Early Glycation Products Produce Pentosidine Cross-links on Native Proteins

NOVEL MECHANISM OF PENTOSIDINE FORMATION AND PROPAGATION OF GLYCATION*

Paulraj ChellanDagger and Ram H. NagarajDagger §

From the Dagger  Center for Vision Research, Department of Ophthalmology, Case Western Reserve University and University Hospitals of Cleveland, Cleveland, Ohio 44106 and the § Department of Pharmacology, Case Western Reserve University, Cleveland, Ohio 44106

Received for publication, September 20, 2000, and in revised form, October 16, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Bovine lens alpha -crystallin was immobilized on EAH-Sepharose gel and glycated using D-ribose. Incubation with 500 and 100 mM D-ribose for 2 and 15 days produced short-term glycated (STGP gel) and long-term glycated proteins (LTGP gel). Both STGP and LTGP gels produced oxygen free radicals. Hydroxyl radical production was twice that in STGP gel compared with the LTGP gel. Incubation with the glycated gels produced pentosidine in a mixture of N-alpha -acetylarginine N-alpha -acetyllysine, bovine lens proteins (BLP), and lysozyme; the amounts measured with STGP gel were higher than those with LTGP gel. Reactive oxygen species scavengers decreased the formation of pentosidine. Pentosidine was also formed in BLP when incubated with water-insoluble proteins extracted from aged or brunescent human lenses. Early glycated proteins from aged or diabetic lenses were bound to a boronate affinity column, the protein-containing gel was incubated with BLP, and pentosidine was measured in the incubation mixtures. With this method we found that diabetic lens proteins produced more pentosidine on BLP than did aged lens proteins. Further investigation indicates that two and three carbon carbohydrates possibly formed from oxidative cleavage of early glycation products are involved in pentosidine formation. Based on our findings, we propose a novel pathway for pentosidine formation on native proteins from glycated proteins.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The Maillard reaction involves reaction of amino groups on proteins with aldehydes and ketones to produce advanced glycation end-products, or AGEs.1 The reaction products include amino acid cross-links, fluorophores, and chromophores on proteins (1, 2). AGEs can bind to specific receptors on cells to cause intracellular oxidative stress as well as the synthesis of growth factors and cytokines (3-6), and the end result is usually damage to the affected tissues (7, 8).

Many tissues have increased AGE content with aging, but increased AGEs are also associated with specific pathologies such as formation of cataracts (9), Alzheimer's disease (10), amyloidosis (11), atherosclerosis (12), and diabetic retinopathy (13, 14). A direct role for AGEs in diabetes was proposed when it was found that AGE infusion into normal rats produced diabetic changes (15). In addition, pharmacological intervention to block the effects of AGEs appears to prevent certain complications of diabetes (16, 17).

Cataract formation is a multifactorial process. One mechanism by which glycation damages proteins is through production of reactive oxygen species (ROS), and various studies link the production of glycation products and the formation of ROS (18-22). Ample evidence indicates that ROS contribute to lens protein damage (23-25), but it is not clear how ROS could be produced within the lens. Recent studies suggest that lens pigments, in the presence (26) or absence of ultraviolet light (27), could generate ROS.

The Amadori product, the initial reaction product in the Maillard reaction, remains almost constant within normal aging lenses, but it occurs at much higher levels in diabetic and senile cataractous lenses (28, 29). Numerous studies document the formation of AGEs in lens proteins during aging and cataractogenesis (9, 30-32). In fact, Ortwerth et al. (33) found that ascorbate-derived AGEs can produce ROS, and human lenses contain relatively large amounts of ascorbate. Oxidation of ascorbate produces highly reactive compounds, including dicarbonyls that can form AGEs (34, 35).

We reasoned that, if glycation products are a source of ROS in the lens, continued formation of ROS could account for cumulative damage to lens crystallins during aging and cataractogenesis. However, we made the surprising discovery that glycated proteins can produce pentosidine, a protein cross-linking AGE on native unmodified lens proteins. Accordingly, we investigated the formation of pentosidine from early and advanced glycation products on alpha -crystallin, and we propose a pathway for pentosidine synthesis from short-chain carbohydrates derived from degradation of early glycation products.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Bovine lenses were obtained from Pel-Freez Biologicals, Roger, AR. EAH-Sepharose was purchased from Amersham Pharmacia Biotech, Piscataway, NJ. Lysozyme, cytochrome c, Chelex-100, deferoxamine, alpha -ketoglutarate, luminol, thiourea, N-alpha -acetyllysine, and N-alpha -acetylarginine were obtained from Sigma Chemical Co. EDC and salicylate were purchased from Aldrich. Furosine standard was from Neosystem, France. Normal and diabetic human lenses were obtained from the National Disease Research Interchange and the Cleveland Eye Bank. Human brunescent lenses were obtained from India (J. N. Medical College Hospital, Aligarh, India). All buffers (unless otherwise mentioned) were prepared with Chelex-100-treated water and, after preparation, were passed through a Chelex-100 column to remove any remaining metal ions.

Purification of alpha -Crystallin-- After decapsulation, bovine lenses were homogenized with a hand-held glass homogenizer in 50 mM Tris/HCl buffer (pH 7.4) containing 0.2 M KCl, 1.0 mM EDTA, 10 mM mercaptoethanol, and 0.05% sodium azide. The homogenate was centrifuged for 20 min at 20,000 × g. The supernatant containing the bovine lens proteins (BLP) was dialyzed against water for 24 h. alpha -Crystallin (mixture of alpha A and alpha B) was isolated from BLP by gel filtration chromatography on Sephacryl S-200 (36). The pooled alpha -crystallin fraction from the column was dialyzed against 4 liters of phosphate-buffered saline for 48 h and lyophilized.

Immobilization of Proteins on EAH-Sepharose-- alpha -Crystallin or lysozyme was immobilized on EAH-Sepharose gel (illustrated in Scheme I). Five milliliters of EAH-Sepharose was washed three times with water and adjusted to pH 4.5 with dilute HCl. The gel was then collected in a conical tube and suspended in 10.0 ml of water with 100 mg of alpha -crystallin and 191 mg of EDC. The contents were gently mixed at 4 °C for 12 h. The pH of the mixture was maintained by adding dilute NaOH. At the end of the reaction, the gel was filtered and thoroughly washed five times, alternating 0.1 M sodium acetate buffer (pH 4.0) with 0.5 M NaCl and 0.1 M Tris-HCl buffer (pH 8) with 0.5 M NaCl. The washed and immobilized protein preparation was stored at 4 °C until use.



View larger version (26K):
[in this window]
[in a new window]
 
Scheme 1.   Preparation of STGP and LTGP gels. alpha -Crystallin was immobilized on EAH-Sepharose in the presence of EDC. It was then glycated with 500 mM D-ribose for 2 days in the case of STGP gel and with 100 mM for 15 days in the case of LTGP gel. The ST and LT glycated gels were incubated with BLP or lysozyme or amino acids. The supernatant was used for analysis.

Preparation of STGP and LTG Gels-- STGP gel (alpha -crystallin or lysozyme) was prepared by reacting EAH-Sepharose-immobilized proteins with 500 mM D-ribose for 2 days at 37 °C in 50 mM phosphate buffer (pH 7.4), and LTGP gel was prepared by reacting the proteins with 100 mM D-ribose for 15 days at 37 °C. After glycation, the gels were washed extensively with water to remove unreacted ribose and stored at 4 °C until use.

Formation of Superoxide Anion from Glycated alpha -Crystallin-- Superoxide anion production by STGP and LTGP gels was measured by cytochrome c reduction, as described by Bhuyan and Bhuyan (37). Superoxide dismutase-inhibitable cytochrome c reduction was taken to be a measure of superoxide anion. STGP and LTGP gels (100 mg each) were incubated in 50 mM sodium phosphate buffer (pH 7.4) at room temperature with slow stirring. Aliquots were withdrawn at fixed time intervals for cytochrome c reduction assay.

Formation of Hydroxyl Radical from Glycated alpha -Crystallin-- Hydroxyl radical production by glycated gels (from alpha -crystallin) was measured by the salicylate hydroxylation method. Typically, 100 mg of STGP- or LTGP gel was incubated with salicylate. The amount of 2,3-dihydroxy benzoate formed was assayed by a spectrometric method (38) described by Bhuyan and Bhuyan (37).

Estimation of Pentosidine in Glycated Protein-- STGP and LTGP gels (100 mg each) (from alpha -crystallin) were acid hydrolyzed in 6 N HCl for 16 h at 110 °C. The contents were dried in a Speed-Vac concentrator (Savant Instruments, Inc. Farmingdale, NY), rehydrated in 200 µl of water, and filtered through a 0.2-µm filter. Pentosidine was measured by the HPLC method as described previously (9) and quantified by comparison with a standard curve for synthetic pentosidine.

Incubation of BLP or Lyzozyme with STGP and LTGP Gels-- The STGP and LTGP gels (from alpha -crystallin or lyzozyme) were washed 10 times with 50 mM sodium phosphate buffer (pH 7.4) before incubation. BLP or lyzozyme (2 mg/ml) was incubated with the STGP- or LTGP gels (100 mg) in 50 mM phosphate buffer (pH 7.4) at 37 °C with gentle mixing for up to 7 days. The final volume of the reaction mixture was 1.0 ml. BLP incubated with unglycated alpha -crystallin (EAH-Sepharose bound) served as control. Aliquots (0.2 ml) were drawn at regular time intervals. In some experiments with alpha -crystallin immobilized gels, we added ROS quenchers (1.0 mM luminol, 5 mM alpha -ketoglutarate, 5 mM mannitol), metal ion chelator (1 mM deferoxamine), or FeCl3 (100 µM) at the start of the reaction. Pentosidine was measured by HPLC.

Incubation of N-alpha -Acetyllysine + N-alpha -Acetylarginine with STGP and LTGP gels-- N-alpha -Acetyllysine (5 mM) and N-alpha -acetylarginine (5 mM) were incubated at 37 °C in 50 mM phosphate buffer (pH 7.4) as described above for BLP. Aliquots of the supernatant were taken after 3 and 7 days for pentosidine measurement.

Pentosidine Formation under Anaerobic Conditions-- In some experiments, air-tight screw cap tubes with an inlet for argon were used to incubate 100-mg STGP- or LTGP gel with BLP under anaerobic conditions. Otherwise, incubation conditions were as indicated earlier. Argon was bubbled through the mixture for 20 min and the argon-air mixture was removed with a vacuum pump. The tubes were then tightly sealed and incubated at 37 °C for 3 days. Controls included nonglycated protein gels and glycated gels incubated without proteins. In addition, samples were also incubated simultaneously under aerobic conditions for comparison.

Formation of Pentosidine from Water-insoluble Human Lens Proteins-- Water-insoluble proteins (WI) from nondiabetic aged (age: 67 years) or brunescent lenses (age: 76 years), were prepared as described by Shamsi et al. (39). 5 mg of WI was washed thoroughly five times with 1 ml of 50 mM sodium phosphate buffer (pH 7.4). After the final wash, 2.0 mg of BLP was added, and the sample was incubated at 37 °C for 7 days. Aliquots (0.2 ml) were taken at 3 and 7 days to measure pentosidine. Furosine content in the WI before and after incubation was measured by HPLC (Alltech, Dearfield, IL) using a furosine-dedicated column (40). For some incubations, the WI protein extract was reduced with sodium borohydride. Incubations of WI with sodium phosphate buffer alone served as a control.

Binding of Early Glycation Products from Human Lenses to Affinity Matrix-- Water-soluble lens protein (WS) was isolated (34) from age- and wet-weight-matched normal and diabetic (nuclear cataractous lenses from patients with Type II diabetes, diabetes duration: >10 years) human lenses. Two lenses (200-240 mg) from donors of 60-70 years of age were used for each sample. The samples were dialyzed against 50 mM sodium phosphate buffer (pH 7.8), and loaded onto a previously equilibrated (50 mM phosphate buffer) Affi-Gel-601 boronate column (Bio-Rad Laboratories, CA). The amount of protein bound to the column was calculated by subtracting the amount of unbound proteins from the amount loaded on the column. After binding of WS samples, the gel was thoroughly washed with buffer and then used in incubations with 2.0 mg of BLP in sodium phosphate buffer at 37 °C for up to 7 days. Some experiments used N-alpha -acetylarginine (5 mM) + N-alpha -acetyllysine (5 mM) in the place of BLP. In other experiments, the gel was reduced with sodium borohydride before incubation. Aliquots from the supernatant were assayed for pentosidine.

Formation of Pentosidine from Short-chain Carbohydrates-- N-alpha -Acetylarginine and N-alpha -acetyllysine were incubated with two and three carbon carbohydrates. N-alpha -Acetylarginine and N-alpha -acetyllysine (5 mM each) were incubated in 50 mM phosphate buffer (pH 7.4) with 5 mM carbohydrate at 37 °C. Aliquots were drawn at 24 and 48 h, and pentosidine was measured after acid hydrolysis (6 N HCl, 110 °C, 16 h).


                              
View this table:
[in this window]
[in a new window]
 
Table I
Effect of ± oxygen in the formation of pentosidine from STGP and LTGP gels
BLP (2 mg/ml in 50 mM phosphate buffer, pH 7.4) was incubated with 100 mg of STGP and LTGP gel at 37 °C in the presence and absence of oxygen for 3 days. Pentosidine in BLP was estimated by HPLC.

Other Procedures-- SDS-PAGE used 15% gels under reducing conditions according to the method of Laemmli (41). Amino acid content of acid-hydrolyzed proteins was measured by the ninhydrin reaction (34), and protein was measured by the Bradford method using a Bio-Rad protein assay kit with bovine serum albumin as a standard.

Sodium borohydride (SBH) reductions involved incubating 5 mg of protein with 5 mM SBH for 2 h at room temperature at pH 9.0 with slow stirring. Unreacted SBH was removed by washing the protein (WI).

Statistics-- Mean differences were evaluated by one-way analysis of variance using StatView Software (SAS Institute, Inc., Cary, NC). Fisher's protected least significant difference test was employed in these calculations. We considered a p value of <0.05 statistically significant. In all figures the means that do not share a common superscript are statistically different at p < 0.05.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We found no pentosidine in control incubations where EAH-Sepharose immobilized proteins with or without glycation were incubated with buffer alone. These controls rule out the possibility of pentosidine leaching from the gel or the formation of pentosidine on the gel itself.

Pentosidine Content of Immobilized Glycated alpha -Crystallin-- Pentosidine was measured by HPLC and expressed as nanomoles per gram of gel. LTGP had nearly twice the amount of pentosidine (4.8 ± 0.3 nmol/g of gel) as compared with STGP (2.5 ± 0.1 nmol/g of gel). We were unable to quantify the Amadori product of the ribose reaction with protein amino groups, because there are no specific assays for it. Measurements of pentosidine indicate that LTGP accumulated more AGEs than did STGP. However, as suggested by the studies of Booth et al. (42), we expected STGP to accumulate more Amadori product under the incubation conditions of our experiments.

Superoxide Anion and Hydroxyl Radicals from Immobilized Glycated alpha -Crystallin-- We used superoxide dismutase-inhibitable reduction of cytochrome c as a measure of superoxide anion. Fig. 1A shows that superoxide anion was minimal with unmodified alpha -crystallin (coupled to gel) but was significant in glycated alpha -crystallin (coupled to gel). SOD inhibited superoxide anion production from both STGP and LTGP gels. Based on the data, we calculated that the amount produced by STGP gel and LTGP gel was 9.5 ± 2.1 nmol/h/g of gel and 7.8 ± 2.0 nmol/h/g of gel, respectively. Hydroxyl radical production was twice that in STGP gel (6.2 ± 2.3 µmol/h/g of gel) compared with the LTGP gel (3.0 ± 0.9 µmol/h/g of gel) (Fig. 1B).



View larger version (40K):
[in this window]
[in a new window]
 
Fig. 1.   A, formation of superoxide anion from STGP and LTGP gels. Superoxide dismutase-inhibitable reduction of cytochrome c was measured at 550 nm. A typical experiment used 100 mg of glycated gel. Incubation conditions are described in the text. Means that do not share a common superscript letter are statistically significant at p < 0.05. B, formation of hydroxyl radicals from STGP and LTGP gels. STGP and LTGP gels were incubated with salicylate, and the amount of 2,3-dihydroxybenzoate formed was measured spectrophotometrically. Control experiments contained the gel coupled to unglycated alpha -crystallin. Means that do not share a common superscript letter are statistically significant at p < 0.05.

Pentosidine Formation in BLP Incubated with Glycated alpha -Crystallin-- The STGP and LTGP gels prepared from incubation of EAH-Sepharose-alpha -crystallin with ribose were washed thoroughly before every incubation to remove loosely bound glycated proteins and any breakdown products formed during storage. The gels were then incubated with BLP. Pentosidine was measured after acid hydrolysis of an aliquot of the incubation mixture. HPLC chromatograms showed pentosidine as a well-resolved peak from samples in which BLP incubated with STGP and LTGP gels (Fig. 2A). Fig. 2B shows that the pentosidine content in both incubations nearly doubled at 7 days compared with the amount at 3 days. The STGP gel produced two to three times as much pentosidine as did the LTGP gel (p < 0.05). These results indicate that pentosidine is produced from carbohydrates derived from glycated proteins, and the early glycation products (Amadori and Schiff's base) are the precursors.



View larger version (18K):
[in this window]
[in a new window]
 
Fig. 2.   Formation of pentosidine in BLP incubated with STGP and LTGP gels. A, pentosidine was estimated by HPLC. BLP (2.0 mg/ml) was incubated with 100 mg of STGP or LTGP gels for 3 or 7 days as described in the text. Control experiments contained unglycated EAH-alpha -crystallin + BLP. Means that do not share a common superscript letter are statistically significant at p < 0.05. A, HPLC tracing of pentosidine standard and pentosidine produced on BLP. B, Pentosidine in BLP incubated with glycated gels. BLP incubated with unglycated alpha -crystallin (EAH-Sepharose-bound) served as control. Means that do not share a common superscript letter are statistically significant at p < 0.05.

Effect of ROS Quenchers and a Metal Ion Chelator on Pentosidine Formation-- STGP and LTGP gels were incubated with BLP for 7 days in the presence or absence of a ROS quencher or deferoxamine or FeCl3. As can be seen in Fig. 3, addition of alpha -ketoglutarate (a scavenger of H2O2) most effectively inhibited pentosidine formation in BLP incubated with SGTP gels; pentosidine was approximately half that in samples incubated without the ROS quencher. Luminol, an O&cjs1138;2 scavenger, only marginally inhibited pentosidine formation, and thiourea, an OH· scavenger, inhibited it by ~30%. The effects were not as great in incubations with LTGP gels, but alpha -ketoglutarate and thiourea caused significant (p < 0.05) inhibition. The metal ion chelator, deferoxamine, was ineffective. Addition of 100 µM FeCl3 enhanced pentosidine formation in both STGP and LTGP gels. The increase was 17% with STGP and 73% with LTGP gel. These results suggest that H2O2 is an important constituent in pentosidine synthesis from glycated proteins.



View larger version (38K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of ROS quenchers on the formation of pentosidine. BLP (2.0 mg/ml) was incubated with 100 mg each of STGP and LTGP gel in the presence or absence of indicated ROS quenchers for 7 days. Pentosidine was measured in BLP after the incubation. Means that do not share a common superscript letter are statistically significant at p < 0.05.

Effect of Lack of Oxygen-- To assess the importance of oxygen in the formation of pentosidine, we did some incubations in the absence of oxygen. Table I shows that pentosidine was decreased ~64 and 98% in STGP and LTGP gels in the absence of oxygen, which indicates that oxidative reactions mediated by ROS are necessary for pentosidine formation.


                              
View this table:
[in this window]
[in a new window]
 
Table II
Formation of pentosidine from short-chain carbohydrates
N-alpha -Acetyllysine and N-alpha -acetylarginine (5 mM each) were incubated with 5 mM each of the indicated carbohydrate in 50 mM sodium phosphate buffer, pH 7.4, at 37 °C for 1 and 2 days. Pentosidine was measured after acid hydrolysis of the incubation mixture.

Covalent Cross-linking of BLP Incubated with STGP and LTGP Gels-- SDS-PAGE revealed that BLP underwent covalent cross-linking upon incubation with glycated gels. We found cross-linked proteins of molecular mass 40-45 kDa in both STGP and LTGP gel incubated proteins (Fig. 4A). STGP gels incubated with BLP produced higher levels of these proteins than comparable incubations with LTGP gels, suggesting that covalent cross-linking possibly occurred as a result of pentosidine and other AGEs in BLP. Results of densitometric analysis showed that, after 7 days of incubation, STGP gel produced nearly three times as much cross-linked proteins as did the LTGP gel (Fig. 4B).



View larger version (56K):
[in this window]
[in a new window]
 
Fig. 4.   A, covalent cross-linking of BLP on incubation with STGP and LTGP gels. BLP (2 mg/ml) was incubated with STGP or LTGP gel in phosphate buffer, and aliquots were drawn at 3 and 7 days and analyzed by SDS-PAGE (15% gel). Lanes 1-4, 3 days incubation; lanes 5-8, 7 days incubation; lane 9, molecular weight markers. Lanes 1 and 5, BLP incubated with unglycated EAH-Sepharose-alpha -crystallin for 3 and 7 days; lanes 2 and 6, BLP incubated with STGP gel. Lanes 3 and 7, BLP incubated with LTGP gel; lanes 4 and 8, BLP alone. STGP and LTGP gels with buffer alone was run simultaneously but showed no protein bands. B, densitometric analysis of cross-linked proteins of 40-45 kDa.

Lyzozyme and N-alpha -Acetylarginine + N-alpha -Acetyllysine Incubated with Gels-- The amount of pentosidine formed from lysozyme after 3 and 7 days of incubation with STGP gel was 9.7 ± 1.3 and 13.2 ± 0.9 pmol/µmol of amino acids, whereas in LTGP gel measured at the same time, it was 2.5 ± 0.8 and 5.3 ± 0.6 pmol/µmol of amino acids (Fig. 5A). Again, the amounts measured in STGP gel were higher than those in LTGP gel. The pentosidine levels in the STGP gel samples after 7 days incubation with lyzozyme were about half those measured in BLP incubated under similar conditions.



View larger version (43K):
[in this window]
[in a new window]
 
Fig. 5.   Pentosidine formation in Lyzozyme (A) and in N-alpha -acetylarginine + N-alpha -acetyllysine incubation mixture (B). STGP and LTCP gels (100 mg) were incubated with lysozyme (2 mg/ml) or with N-alpha -acetylarginine + N-alpha -acetyllysine (5 mM each) for 3 and 7 days. Lyzozyme (or amino acid mixture) incubated with unglycated alpha -crystallin (EAH-Sepharose-bound) served as control. Means that do not share a common superscript letter are statistically significant at p < 0.05.

In another set of experiments, gels were incubated with N-alpha -acetylarginine + N-alpha -acetyllysine instead of BLP. Arginine and lysine are precursor amino acids for pentosidine, and we found that significant amounts of pentosidine were produced in these incubations. The levels were 30-44% higher following incubation with STGP gel than with the LTGP gel (Fig. 5B). Taken together, these results show that pentosidine formation is not specific to BLP alone and that it forms in other proteins as well.

Pentosidine in BLP Incubated with Glycated Lysozyme-- Lysozyme was immobilized on EAH-Sepharose and glycated using D-ribose. STGP and LTGP gels were prepared by incubating with D-ribose for 2 and 15 days. As shown in Fig. 6, incubations with the STGP gel consistently yielded more pentosidine than did the LTGP gel, but pentosidine formation in both increased from 3 to 7 days.



View larger version (39K):
[in this window]
[in a new window]
 
Fig. 6.   Pentosidine formation in BLP and (N-alpha -acetylarginine + N-alpha -acetyllysine) incubated with lyzozyme STGP and LTGP gels. STGP and LTGP gels were prepared by coupling lyzozyme with EAH-Sepharose followed by short-term and long-term incubation with D-ribose (see "Experimental Procedures"). Other details are same as in Fig. 2. A, pentosidine in BLP incubated with lysozyme-glycated gel, B, pentosidine in amino acids incubated with lysozyme-glycated gel. BLP incubated with EAH-Sepharose-bound unglycated lyzozyme served as control. Means that do not share a common superscript letter are statistically significant at p < 0.05.

STGP or LTGP gels were also incubated with a mixture of N-alpha -acetylarginine + N-alpha -acetyllysine, and the results were similar to those obtained with BLP (Fig. 6B). Together these incubation experiments confirm that pentosidine formation on unmodified native proteins occurs not only with glycated alpha -crystallin but also with other proteins.

Formation of Pentosidine in BLP Incubated with Water-insoluble Human Lens Proteins-- To determine whether these lens proteins could mimic the effects of in vitro glycated proteins, we incubated WI proteins from aged or brunescent lenses with BLP. This experiment also helped us to establish that glucose-derived early glycation products produce pentosidine. We washed the WI thoroughly with water before incubation to remove all soluble protein and incubated them with BLP (2 mg/ml) for 3 and 7 days. Analysis of BLP after incubation revealed that proteins from aged lenses produced nearly 3-fold higher levels of pentosidine (Fig. 7, A and B) than proteins from brunescent lenses. Sodium borohydride treatment of WI before incubation with BLP almost completely suppressed pentosidine formation (Fig. 7B). Furosine content of WI protein of aged and brunescent lenses was estimated before and after incubation. The amount of furosine in WI of aged and brunescent lenses were similar (~500 pmol/µmol of amino acids) (Fig. 7C) but was completely degraded after 7 days of incubation (Fig. 7D). As expected, sodium borohydride treatment resulted in the reduction of the Amadori, and therefore, furosine was not detected in these samples (Fig. 7D). These results show that proteins glycated in vivo can produce pentosidine on nonglycated proteins and that early glycation products are pentosidine precursors.



View larger version (41K):
[in this window]
[in a new window]
 
Fig. 7.   A and B, formation of pentosidine in BLP incubated with WI proteins from aged and brunescent cataractous human lenses. Washed WI proteins (5 mg) were incubated with BLP (2 mg/ml) as described in the text. C and D, furosine content of WI before and after incubation with BLP. Furosine was estimated by HPLC. For some experiments, WI was reduced by SBH before incubation with BLP. Unreacted SBH was removed by washing proteins several times with buffer. Means that do not share a common superscript letter are statistically significant at p < 0.05.

Incubation with Affinity Matrix-bound Early Glycation Products-- We calculated that 18.5 and 28.8 mg of protein from early glycation products were bound to a boronate affinity gel from incubations with aged and diabetic lenses. The gel was then incubated with BLP or a mixture of N-alpha -acetylarginine + N-alpha -acetyllysine. As Fig. 8 shows, the bound proteins produced pentosidine in BLP. The amounts formed from diabetic lens proteins were higher than those formed by aged lenses after either 3 or 7 days of incubation. Similarly, when a mixture of N-alpha -acetylarginine + N-alpha -acetyllysine was added to the matrix-bound diabetic lens proteins, pentosidine formation was nearly twice that from comparable samples from aged lenses. Neither control incubations of BLP with gel, but without bound lens proteins, nor incubations with amino acids or BLP produced pentosidine. We concluded that diabetic lenses produce more pentosidine than nondiabetic lenses of comparable age, and that early glycation products promote pentosidine formation.



View larger version (26K):
[in this window]
[in a new window]
 
Fig. 8.   Formation of pentosidine in BLP from affinity matrix-bound early glycation products of human lenses. Early glycation products from WS extracts of diabetic and aged lenses were bound to a boronate affinity gel by passing through the column. The matrix was extensively washed with sodium phosphate buffer, and 100 mg of gel was incubated with 2 mg of BLP or with a mixture of N-alpha -acetylarginine + N-alpha -acetyllysine (5 mM each) for 3 and 7 days as described in the text. We used 100 µg of BLP and 833 nmol of amino acids for pentosidine measurements. The results are expressed as picomoles of pentosidine per gram of gel.

Pentosidine Formation from Short-chain Carbohydrates-- To determine which of the fragments derived from early glycation products might serve as precursors of pentosidine, we incubated two and three carbon carbohydrates with a mixture of N-alpha -acetylarginine N-alpha -acetyllysine and measured the amount of pentosidine formed. Among the carbohydrates tested, glyceraldehyde produced the highest levels of pentosidine followed by glycolaldehyde and glyoxal (Table II). 1H NMR (D2O) and UV absorption spectra of the product from glyceraldehyde were fully compatible with those reported for ribose-derived pentosidine (43) (data not shown). In the case of glycolaldehyde and glyoxal, spectroscopic characterization is necessary to confirm the formation of pentosidine.

Because glyceraldehyde was the major precursor, we have proposed a pathway for pentosidine formation from this compound (Fig. 9). First, condensation of the aldehydic group of glyceraldehyde with the guanidino group of arginine and dehydration yields 1. Elimination of a molecule of formaldehyde yields 2. Oxidation of 2 followed by condensation with a molecule of lysine gives 4, which by cyclization and reaction with a second molecule of glyceraldehyde forms 6. Intramolecular cyclization of 6 followed by elimination of two molecules of water yields pentosidine. In fact, a structure similar to the proposed intermediate 6 has been reported from the reaction of short-chain carbohydrates with arginine and lysine (44).



View larger version (15K):
[in this window]
[in a new window]
 
Fig. 9.   Proposed pathway for pentosidine formation from glyceraldehyde.



    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We reasoned that Amadori products could accumulate in the lens, where proteins are long-lived. These products could continually generate the reactive oxygen species and damage lens proteins. Other investigators had shown that, when high amounts of D-ribose are used for glycation, proteins accumulate the Amadori product, and its degradation is inhibited (42, 45). Therefore, we used a novel preparation in which alpha -crystallin was coupled to EAH-Sepharose and glycated to enrich the lens proteins with Amadori products or AGEs.

Our studies confirm the formation of O&cjs1138;2 and OH· radicals from the glycated proteins. Previous studies from other laboratories demonstrated O&cjs1138;2 production from early glycation products that include 1,2- and 2,3-enolization of the Schiff's base and oxidation of the enolate anion (46-49). We expected higher levels of O&cjs1138;2 from the short-term glycated alpha -crystallin (500 mM ribose, 2 days) than the long-term glycated alpha -crystallin (100 mM, 15 days), but we observed only modest increases. This may be due to the presence of early glycation products in the long-term glycated alpha -crystallin.

A puzzle was the production of OH· from glycated proteins. This radical could be produced via the Fenton reaction from H2O2. Phosphate buffer has trace amounts of cupric and ferric ions. To remove metal ions we passed our buffers through a Chelex-100 column, but this may not have removed all trace metal ions. In fact, a recent study showed that buffers passed through Chelex-100 resin retain some cupric ions (50). This may have initiated the Fenton reaction and produced OH·. Additionally, lens proteins themselves may have initiated the Fenton reaction. It is known that lens proteins can bind metal ions in vivo (51), which raises the possibility that the alpha -crystallins from bovine eyes may have redox-active metal ions bound to it.

We found cross-linked proteins of 40-45 kDa in bovine lens proteins that were incubated with glycated proteins, and lens proteins incubated with short-term glycated proteins had higher levels than those incubated with long-term glycated proteins. These observations suggest that the cross-linked proteins are produced by reactions mediated primarily by early glycation products, not likely by AGEs. The finding that pentosidine is formed in BLP, that was incubated with glycated alpha -crystallin, supports this view. In addition, Araki et al. (30) demonstrated immunoreactivity with 40- to 45-kDa proteins in aged and cataractous lenses with antibodies against glucose-derived AGEs. SDS-PAGE studies of lens proteins showed that aged and cataractous lenses have proteins of 40-45 kDa. Spector and colleagues (52, 53) isolated a fluorescent 43-kDa protein from human lenses. They also reported that proteins of 40-45 kDa could be formed from the transitional metal-catalyzed reaction in lens crystallins incubated with ascorbate (54).

We were surprised by the finding of pentosidine in proteins that were incubated with glycated alpha -crystallin. According to the conventional dogma, a pentose sugar, such as ribose, reacts first with a lysine residue on proteins to form an Amadori product, which then reacts with an arginine residue to form pentosidine (43). Based upon results from our own experiments, we believe that pentosidine can form from short-chain carbohydrates. Our experiments show that glyceraldehyde, glycolaldehyde, and glyoxal can produce pentosidine when incubated with N-alpha -acetyllysine + N-alpha -acetylarginine. Whether these carbohydrates were ultimately responsible for pentosidine formation in BLP or lysozyme still needs to be established, probably by analysis of carbohydrates after chemical trapping during the reaction. We believe that the Amadori product or Schiff's base underwent fragmentation through reactive oxygen species-mediated reactions to produce the short-chain carbohydrate intermediates, which then reacted sequentially with lysine and arginine residues to produce pentosidine. The total absence of pentosidine in glycated proteins that were reduced with SBH supports this view. In confirmation of our proposed pathway, Farboud et al. (55) observed pentosidine formation from glycolaldehyde, as we did. Formation of glycolaldehyde and glyoxal as intermediates in glycation was also documented (56, 57).

Our observations with human lens proteins are noteworthy, because they have important implications for human aging and disease. First, we incubated bovine lens proteins with water-insoluble lens proteins isolated from brunescent cataractous lenses. These damaged lenses are completely opaque and highly pigmented, and they contain relatively large amounts of Amadori products and AGEs (9, 51, 58). We found that the furosine content decreased after incubation, indicating degradation of the Amadori product, but loss of this intermediate did not correspond to the formation of pentosidine. Only 26 and 9% of the Amadori product in aged and cataractous lenses could account for the formed pentosidine. We assume that other products were produced along with pentosidine.

In our experiments with boronate affinity column, as expected, diabetic lenses had more Amadori product than aged lenses, as indicated by the amount of affinity gel-bound protein. Bovine lens proteins incubated with the gel formed pentosidine. We did not expect boronate-bound Amadori product to cleave and produce pentosidine. It is possible that early glycation products other than those bound to boronate may have served as pentosidine precursors in these incubations. Nevertheless, these results suggest that the higher levels of pentosidine in diabetic lenses compared with normal lenses (59) is due, in part, to degradation of the relatively higher levels of Amadori product.

We found that oxygen is necessary for pentosidine formation from the Amadori product in the lens. Because there is low oxygen tension in the lens (60), such reactions probably occur only at a very slow rate. In addition, the lens may have other defenses against pentosidine formation, such as aldose reductase, which metabolizes glyceraldehyde, a potential precursor for pentosidine, as shown by our studies.

The formation of pentosidine was not an isolated phenomenon that occurred only from glycated alpha -crystallin. We could reproduce those results by using glycated lysozyme in place of glycated alpha -crystallin and lysozyme in place of BLP. Our results suggest that pentosidine formation from glycated proteins occurs not only in the lens but may also occur in other tissue proteins in the body as well.

In vitro incubation experiments have shown progression of cross-linking of glycated proteins in the absence of sugar (61, 62). In diabetes, certain complications progress during periods of good glycemic control (63). These observations suggest that biochemical processes that are set in motion in the presence of sugar or under poor glycemic control can continue even after a return to normoglycemia. Our finding that pentosidine and possibly other AGEs can be formed from degradation of early glycation products in the absence of sugar offers one potential scenario.

In summary, our studies focused upon the formation of pentosidine from glycation. We propose a novel pathway of pentosidine formation that could illuminate mechanisms of AGE formation in diabetes and aging as well as suggest potential therapeutic interventions.


    ACKNOWLEDGEMENTS

We thank Dr. Marcus A. Glomb, Technical University, Berlin, Germany for critically reading this manuscript. We are grateful to Konstantina Angelis, Department of Biochemistry, Case Western Reserve University for densitometric analysis and Kermit Johnson, Department of Chemistry, University of Michigan, for NMR analyses.


    FOOTNOTES

* This work was supported by National Institutes of Health Grants R01EY-09912 (to R. H. N.) and P30EY-11373 (Case Western Reserve University Visual Science Center) and Research to Prevent Blindness, New York.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Dept. of Ophthalmology, Case Western Reserve University, Wearn Bldg. 643, Cleveland, OH 44106. Tel.: 216-844-1132; Fax: 216-844-7962; E-mail: nhr@po.cwru.edu.

Published, JBC Papers in Press, November 13, 2000, DOI 10.1074/jbc.M008626200


    ABBREVIATIONS

The abbreviations used are: AGEs, advance glycation end-products; EAH, epoxy aminohexyl; EDC, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; BLP, bovine lens proteins; ROS, reactive oxygen species; WS, water-soluble protein; WI, water-insoluble protein; HPLC, high performance liquid chromatography; STGP, short-term glycated proteins; LTGP, long-term glycated proteins; SBH, sodium borohydride; PAGE, polyacrylamide gel electrophoresis.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Monnier, V. M., Nagaraj, R. H., Portero-Otin, M., Glomb, M., Elgawish, A. H., Sell, D. R., and Friedlander, M. A. (1996) Nephrol. Dial. Transplant. 11, 20-26[Medline] [Order article via Infotrieve]
2. Vlassara, H., Bucala, R., and Striker, L. (1994) Lab. Invest. 70, 138-151[Medline] [Order article via Infotrieve]
3. Araki, N., Higashi, T., Mori, T., Shibayama, R., Kawabe, Y., Kodama, T., Takahashi, K., Shichiri, M., and Horiuchi, S. (1995) Eur. J. Biochem. 230, 408-415[Abstract]
4. Vlassara, H. (1992) Diabetes 41, 52-56[Medline] [Order article via Infotrieve]
5. Schmidt, A. M., Hori, O., Brett, J., Yan, S. D., Wautier, J. L., and Stern, D. (1994) Arterioscl. Thromb. 14, 1521-1528[Abstract]
6. Schmidt, A. M., Hori, O., Cao, R., Yan, S. D., Brett, J., Wautier, J. L., Ogawa, S., Kuwabara, K., Matsumoto, M., and Stern, D. (1996) Diabetes 45, S77-S80[Medline] [Order article via Infotrieve]
7. Vlassara, H., Brownlee, M., Manogue, K. R., Dinarello, C. A., and Pasagian, A. (1988) Science 240, 1546-1548[Medline] [Order article via Infotrieve]
8. Westwood, M. E., and Thornalley, P. J. (1996) Immunol. Lett. 50, 17-21[CrossRef][Medline] [Order article via Infotrieve]
9. Nagaraj, R. H., Sell, D. R., Prabhakaram, M., Ortwerth, B. J., and Monnier, V. M. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 10257-10261[Abstract]
10. Smith, M. A., Taneda, S., Richey, P. L., Miyata, S., Yan, S. D., Stern, D., Sayre, L. M., Monnier, V. M., and Perry, G. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 5710-5714[Abstract]
11. Miyata, T., Hori, O., Zhang, J., Yan, S. D., Ferran, L., Iida, Y., and Schmidt, A. M. (1996) J. Clin. Invest. 98, 1088-1094[Abstract/Free Full Text]
12. Kume, S., Takeya, M., Mori, T., Araki, N., Suzuki, H., Horiuchi, S., Kodama, T., Miyauchi, Y., and Takahashi, K. (1995) Am. J. Pathol. 147, 654-667[Abstract]
13. Hammes, H. P., Martin, S., Federlin, K., Geisen, K., and Brownlee, M. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 11555-11558[Abstract]
14. Stitt, A. W., Li, Y. M., Gardiner, T. A., Bucala, R., Archer, D. B., and Vlassara, H. (1997) Am. J. Pathol. 150, 523-531[Abstract]
15. Vlassara, H., Fuh, H., Makita, Z., Krungkrai, S., Cerami, A., and Bucala, R. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 12043-12047[Abstract]
16. Brownlee, M. (1994) Diabetes 43, 836-841[Medline] [Order article via Infotrieve]
17. Soulis, T., Sastra, S., Thallas, V., Mortensen, S., Wilken, M., Clausen, J., Bjerrum, O., Petersen, H., Lau, J., Jerums, G., Boel, E., and Cooper, M. (1999) Diabetologia 42, 472-479[CrossRef][Medline] [Order article via Infotrieve]
18. Giardino, I., Edelstein, D., and Brownlee, M. (1996) J. Clin. Invest. 97, 1422-1428[Abstract/Free Full Text]
19. Linetsky, M., James, H., and Ortwerth, B. (1999) Exp. Eye Res. 69, 239-248[CrossRef][Medline] [Order article via Infotrieve]
20. Ortwerth, B. J., Prabhakaram, M., Nagaraj, R. H., and Linetsky, M. (1997) Photochem. Photobiol. 65, 666-672[Medline] [Order article via Infotrieve]
21. Mullarkey, C. J., Edelstein, D., and Brownlee, M. (1990) Biochem. Biophys. Res. Commun. 173, 932-939[Medline] [Order article via Infotrieve]
22. Elgawish, A., Glomb, M., Friedlander, M., and Monnier, V. M. (1996) J. Biol. Chem. 271, 12964-12971[Abstract/Free Full Text]
23. Spector, A. (1995) FASEB. J. 9, 1173-1182[Abstract/Free Full Text]
24. Giblin, F., Padgaonkar, V., Leverenz, V., Lin, L., Lou, M., Unakar, N., Dang, L., Dickerson, J. J., and Reddy, V. (1995) Exp. Eye Res. 60, 219-235[Medline] [Order article via Infotrieve]
25. Srivastava, S. K., and Ansari, N. H. (1988) Diabetes 37, 1505-1508[Abstract]
26. Linetsky, M., James, H. L., and Ortwerth, B. J. (1996) Exp. Eye Res. 63, 67-74[CrossRef][Medline] [Order article via Infotrieve]
27. Garner, B., Davies, M. J., and Truscott, R. J. W. (2000) Exp. Eye Res. 70, 81-88[CrossRef][Medline] [Order article via Infotrieve]
28. Garlick, R. L., Mazer, J. S., Chylack, L. T., Jr., Tung, W. H., and Bunn, H. F. (1984) J. Clin. Invest. 74, 1742-1749[Medline] [Order article via Infotrieve]
29. Tessier, F., Obrenovich, M., and Monnier, V. (1999) J. Biol. Chem. 274, 20796-20804[Abstract/Free Full Text]
30. Araki, N., Ueno, N., Chakrabarti, B., Morino, Y., and Horiuchi, S. (1992) J. Biol. Chem. 267, 10211-10214[Abstract/Free Full Text]
31. Nagaraj, R. H., Kern, T. S., Sell, D. R., Fogarty, J., Engerman, R. L., and Monnier, V. M. (1996) Diabetes 45, 587-594[Abstract]
32. Ahmed, M., Brinkmann, F. E., Degenhardt, T., Thorpe, S., and Baynes, J. (1997) Biochem. J. 324, 565-570[Medline] [Order article via Infotrieve]
33. Ortwerth, B. J., Linetsky, M., and Olesen, P. R. (1995) Photochem. Photobiol. 62, 454-462[Medline] [Order article via Infotrieve]
34. Nagaraj, R. H., and Monnier, V. M. (1992) Biochim. Biophys. Acta 1116, 34-42[Medline] [Order article via Infotrieve]
35. Shipanova, I. N., Glomb, M. A., and Nagaraj, R. H. (1997) Arch. Biochem. Biophys. 344, 29-36[CrossRef][Medline] [Order article via Infotrieve]
36. Li, L. (1978) Exp. Eye Res. 27, 553-566[Medline] [Order article via Infotrieve]
37. Bhuyan, D., and Bhuyan, K. (1994) Methods Enzymol. 233, 630-639[Medline] [Order article via Infotrieve]
38. Halliwell, B., and Gutteridge, J. M. C. (1999) Free Radicals in Biology and Medicine , 3rd Ed. , pp. 361-365, Oxford University Press, New York
39. Shamsi, F. A., Partal, A., Sady, C., Glomb, M. A., and Nagaraj, R. H. (1998) J. Biol. Chem. 273, 6928-6936[Abstract/Free Full Text]
40. Resmini, P., Pellegrino, L., and Battelli, G. (1990) Ital. J. Food Sci. 2, 173-184
41. Laemmli, U. K. (1970) Nature 227, 680-85[Medline] [Order article via Infotrieve]
42. Booth, A. A., Khalifah, R. G., Todd, P., and Hudson, B. G. (1997) J. Biol. Chem. 272, 5430-5437[Abstract/Free Full Text]
43. Sell, D. R., and Monnier, V. M. (1989) J. Biol. Chem. 264, 21597-21602[Abstract/Free Full Text]
44. Lederer, M. O., and Klaiber, R. G. (1999) Bioorg. Med. Chem. 7, 2499-2507[CrossRef][Medline] [Order article via Infotrieve]
45. Khalifah, R., Baynes, J., and Hudson, B. (1999) Biochem. Biophys. Res. Commun. 257, 251-258[CrossRef][Medline] [Order article via Infotrieve]
46. Smith, P. R., and Thornalley, P. J. (1992) Eur. J. Biochem. 210, 729-739[Abstract]
47. Gillery, P., Monboisse, J. C., Maquart, F. X., and Borel, J. P. (1988) Diab. Metabol. 14, 25-30[Medline] [Order article via Infotrieve]
48. Carubelli, R., Schneider, J. E., Jr., Pye, Q. N., and Floyd, R. A. (1995) Free Radic. Biol. Med. 18, 265-269[CrossRef][Medline] [Order article via Infotrieve]
49. Monboisse, J. C., Gillery, P., Maquart, F. X., and Borel, J. P. (1990) Adv. Exp. Med. Biol. 264, 551-554[Medline] [Order article via Infotrieve]
50. Goldstein, L. E., Leopold, M. C., Huang, X., Atwood, C., Saunders, A. J., Hartshorn, M., Lim, J. T., Faget, K. Y., Muffat, J. A., Scarpa, R. C., Chylack, L. T., Bowden, E. F., Tanzi, R. E., and Bush, A. I. (2000) Biochemistry 39, 7266-7275[CrossRef][Medline] [Order article via Infotrieve]
51. Saxena, P., Saxena, A., Cui, X., Obrenovich, M., Gudipaty, K., and Monnier, V. (2000) Invest. Ophthalmol. Vis. Sci. 41, 1473-1481[Abstract/Free Full Text]
52. Spector, A., Garner, M. H., Garner, W. H., and Roy, D. (1979) Science 204, 1323-1326[Medline] [Order article via Infotrieve]
53. McDermott, M. J., Chiesa, R., and Spector, A. (1989) Curr. Eye Res. 8, 771-779[Medline] [Order article via Infotrieve]
54. Spector, A. (1984) Invest. Ophthalmol. Vis. Sci. 25, 130-146[Medline] [Order article via Infotrieve]
55. Farboud, B., Aotaki-Keen, A., Miyata, T., Hjelmeland, L., and Handa, J. (1999) Mol. Vision 5, 11[Medline] [Order article via Infotrieve]
56. Glomb, M. A., and Monnier, V. M. (1995) J. Biol. Chem. 270, 10017-10026[Abstract/Free Full Text]
57. Nagai, R., Matsumoto, K., Ling, X., Suzuki, H., Araki, T., and Horiuchi, S. (2000) Diabetes 49, 1714-1723[Abstract]
58. Shamsi, F. A., Lin, K., Sady, C., and Nagaraj, R. H. (1998) Invest. Ophthalmol. Vis. Sci. 39, 2355-2364[Abstract]
59. Lyons, T. J., Silvestri, G., Dunn, J. A., Dyer, D. G., and Baynes, J. W. (1991) Diabetes 40, 1010-1015[Abstract]
60. Harding, J. J. (1991) Cataract: Biochemistry, Epidemilogy and Pharmacology , p. 180, Chapman and Hall, London
61. Liggins, J., and Furth, A. J. (1996) Biochem. Biophys. Res. Commun. 219, 186-190[CrossRef][Medline] [Order article via Infotrieve]
62. Kato, H., Shin, H. S., Liang, Z. Q., Nishimura, T., and Hayase, F. (1994) in Maillard Reactions in Chemistry, Food and Health (Labuza, T. P. , Reineccius, G. A. , Monnier, V. M. , and Baynes, J. W., eds) , pp. 309-313, The Royal Society of Chemistry, Cambridge
63. Engerman, R. L., and Kern, T. S. (1987) Diabetes 36, 808-812[Abstract]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.